Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kate Therapeutics
San Diego, California, United Stateskatetx.com ↗
- Ownership
- Private
- Employees
- ~44
- Development stage
- Other
01
Overview
Kate Therapeutics developed next-generation AAV-based gene therapies with a focus on improving delivery specificity and safety. Their lead program KT430 targets XLMTM. The company’s pipeline also includes preclinical assets for DMD, FSHD, DM1, and cardiomyopathies. No clinical results have been reported as all programs are at the preclinical stage at the time of acquisition by Novartis.
- Therapeutic areas
- CardiovascularRare DiseasesNeurology
- Modalities
- Gene therapies (AAV-based)Engineered capsids and gene delivery technologies
- Industry
- Biotech
02
Partnerships
Astellas Pharma – exclusive worldwide license for KT430 program targeting XLMTM
Beyond the preview
Go deeper on Kate Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kate Therapeutics.